 |
市場調查報告書
精準醫療市場-各國電子醫療（e-Health）促銷政策的推進（2018-2025）National eHealth Initiatives Advancing Global Precision Medicine Market, 2018-2025 |
||||||
| 出版商 | Frost & Sullivan | 商品編碼 | 953242 | ||||
| 出版日期 | 內容資訊 | 英文 66 Pages 商品交期: 最快1-2個工作天內 |
|||||
| 價格 |
|
||||||
| 精準醫療市場-各國電子醫療（e-Health）促銷政策的推進（2018-2025） National eHealth Initiatives Advancing Global Precision Medicine Market, 2018-2025 | ||
| 出版日期: 2020年07月28日 | 內容資訊: 英文 66 Pages |
|
來自保險公司的巨大壓力和放寬管制將藥品業務從規範模型轉變為預測/個性化模型，這正在將精密醫學轉變為廣泛接受的產品。伴隨診斷（CDx）和靶向療法（TRx）將用於癌症治療以外的其他領域（傳染病，中樞神經系統（CNS），心血管疾病等），而全組學技術將用作目標分子。它也用於識別。另一方面，電子醫療（e-health）在世界主要國家-愛沙尼亞，芬蘭，加拿大，中國，澳大利亞，台灣，韓國，新加坡，日本等方面取得了重大進展，基礎設施發展和技術進步也正在以大筆投資進行。它被用於包括精密醫學在內的各種醫學領域。
本報告分析了全球精密醫學（PM）市場的結構/趨勢和增長機會，並分析了生態系統的組成部分，當前技術水平和未來技術進步機會以及整體市場規模。趨勢展望，按領域劃分的詳細趨勢，主要的市場促進和製約因素，以及行業利益相關者在未來以及主要國家的當前/未來響應狀態中要解決的問題，尤其是電子醫療（e-health）我們將收集並提供與系統有關的信息。
Taiwan, Estonia, and Finland Emerging as Key Markets Fueling Growth Opportunities in Precision Medicine Informatics
Precision medicine is transitioning toward wider acceptance, due to mounting payer pressures and regulatory changes that are shifting pharma businesses from prescriptive to more predictive and personalized models. Emergence of value-based reimbursement models and healthcare consumerism trends are helping move the treatment model from 'one-size-fits-all' to a stratified and outcome-based targeted therapeutics concept called 'precision medicine' (PM).
Companion diagnostics (CDx) and targeted therapeutics (TRx) are going beyond oncology and spreading more toward therapeutic areas such as infectious diseases, central nervous system (CNS), and cardiovascular diseases. Despite a relatively high success rate for PM R&D assets commercialization in recent years, considerable challenges exist around proving clinical utility and a regulatory and reimbursement framework, which is rigid, decentralized, and non-uniform.
Advances in omics technologies help in identifying molecular targets with the help of molecular insights generated by datasets about the disease pathogenesis. PM informatics is the key component of the PM ecosystem. PM-cognitive analytic platforms capable of leveraging genomic, clinical, financial, and lifestyle data, while delivering actionable clinical insights at the point of care, are gaining market traction. Big Data and Artificial Intelligence (AI) are the key enablers for utilizing the full potential of PM for building predictive models based on multi-omics data, given a big hurdle in the adoption of PM is lack of technology infrastructure.
Genomic sequencing has huge potential to support the COVID-19 outbreak exploration, especially in comprehending the re-emergence of potential COVID-19 outbreaks.
In terms of geographic outlook, although the specific focus on PM research started in the United States and the EU, countries such as Canada, China, Australia, Taiwan, South Korea, Singapore, and Japan have made significant advances in recent years in this area by way of significant investments to develop in-country research and scientific expertise to improve access. Considering the infrastructure requirements for utilizing omics in clinical practice, China and Japan are beating other leading countries in terms of both research initiatives and regulations and infrastructure development.
This research service analyzes the key building blocks for the precision medicine ecosystem to provide strategic imperatives and growth opportunities for key participants. The study captures both the global and regional flavors for PM market opportunity realization such as: market projections, drivers and restraints, country readiness index, and major government and commercial initiatives. The study also provides live case studies and innovative business models for leading companies in the PM space.
